Group items tagged

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

Community Pharmacy England (CPE), the Company Chemists' Association (CCA), the Royal Pharmaceutical Society (RPS) and the National Pharmacy Association (NPA) on Tuesday (5 March) released a joint manifesto for community pharmacy in anticipation of the upcoming general election expected later this year. The manifesto has been designed for widespread use within the community pharmacy sector to facilitate engagement with political parties and parliamentary candidates. In their #VotePharmacy manifesto, the pharmacy bodies have highlighted a robust six-point plan to unleash the potential of pharmacy. Election candidates are urged to express their support in six key areas, which include: Filling the funding gap and committing to long-term sustainable funding to empower pharmacies to deliver more NHS care. Enhancing the community pharmacy workforce to ensure they can meet the evolving needs of patients.

National Pharmacy Association (NPA) urged the NHS England to make local impact assessment a key requirement prior to any recruitment into Primary Care Networks (PCNs) and Clinical Commissioning Groups (CCGs), to help tackle workforce crisis. With inputs from LPCs, PCNs and CCGs should consider the impact of the creation of new roles on all health care providers in the area and on their ability to deliver their objectives on behalf of the NHS, it said. The NPA believes that creation of the Additional Roles Reimbursement Scheme (ARRS) programme is impacting community pharmacy services in some areas and contributing to the ongoing workforce shortage. In a letter addressed to Ed Waller, director of Primary Care for NHS England, NPA chief executive Mark Lyonette highlighted the challenges emerged following a shortage of pharmacists and other members of staff.

The Health and Social Care Committee (HSCC) has announced the appointment of six specialists to scrutinise the government's progress made on its commitments to pharmacy services in England on Wednesday (26 April). "They will work alongside the core members of the Expert Panel to produce a report evaluating Government progress across nine of the Government's own commitments across the four areas. A CQC-style rating from "inadequate" to "outstanding" will be awarded against each specific pledge with a final overall rating given," said DHSC. Professor Dame Jane Dacre, Chair of the Expert Panel, said: "The role of pharmacy in delivering care whether in hospital, the community or primary care has never been more important. "The Government has made a number of commitments aimed at improving pharmacy services and we'll be looking at the progress to achieve these targets. "In the process of our evaluation we'll be hearing from stakeholders from across the industry, including the pharmacy workforce and NHS and independent providers of pharmacy services. We'll be considering pledges covering frontline services as well as the education and training of the workforce." National Pharmacy Association (NPA) chief executive, Mark Lyonette, is one of six panel members with specialist expertise in pharmacy. They will work alongside five standing members who are all renowned healthcare policy experts and professionals. Professor Dame Jane Dacre will chair.

David Webb, the Chief Pharmaceutical Officer for England, acknowledged that the "pressure in the system is high", but urged everyone to "keep our eye on the design" of the NHS plan, adding that the "the objective is to bring the different parts of primary care together" in the patient interest. Speaking during the opening keynote session at the the National Pharmacy Association (NPA) conference held on Thursday (13 October), he added that the NHS plan intends to bring different parts of primary care together to help patients. He said the new integrated care boards (ICBs) are a key strategic framework as they provide the "potential to form partnerships to deliver integrated services across larger populations". "ICBs will want to work with Local Pharmaceutical Committees to plan for the local population and the new community pharmacy clinical leads in ICBs, who have been funded by NHS England, are there to advise." He explained that once an ICB takes over the commissioning of pharmaceutical services (which they are all due to do by April 2023), it could use its funds to commission a local enhanced service as an add on to an advanced service. For instance, a CVD risk assessment could be added to the blood pressure check service.

It's no secret that the world of work can be dangerous. Every day, workers are injured on the job, and in some cases, these injuries can be quite serious. If you're unfortunate enough to find yourself in this situation, it's important to know what steps to take to get the medical care you need. There are several ways to get proper medical aid if you're injured at work, and each option has its own set of benefits and drawbacks. HEALTH INSURANCE If your employer offers health insurance, this will likely be your first port of call when seeking medical care after a workplace injury. The main benefit of using your employer's insurance is that it will usually cover the majority of your medical expenses. However, there are some drawbacks to this option. First, your employer's insurance may only cover treatment from specific doctors or hospitals. This can make it difficult to get the care you need on time. Second, your employer's insurance may not cover all of the costs associated with your injury, leaving you with a hefty bill. Very often, workers consider obtaining private insurance, especially if they're working as ex-pats or freelancers. It is good to note that in these cases, private insurance would then be used in combination with their employer's insurance, giving them a greater degree of coverage. However, even if you're only insuring yourself, this insurance can be beneficial because you'll be able to choose your doctor, and you may have a greater range of coverage.

Pharmacy bodies have welcomed the new minister in charge of the profession amid warnings that he will find the sector in a state that is "more fragile that ever" due to "untenable funding and workforce pressures". Neil O'Brien was re-appointed as parliamentary under secretary of state in the Department of Health and Social Care (DHSC) on October 25 and was later assigned the pharmacy brief. The Conservative MP for Harborough - who will have a wide-ranging portfolio of responsibilities, including primary care and pharmacy - has taken over the position from Will Quince MP, who had a brief stint as pharmacy minister but remains at the department on a different role. O'Brien was was handed a junior minister's job at DHSC on 7 September 2022 in the government led by Liz Truss but fellow Conservative Quince was assigned primary care duties including pharmacy. Welcoming him to his new role, The Company Chemists' Association said that the minister would find that the community pharmacy sector was "more fragile than ever" with untenable pressures over funding and workforce.

The Royal Pharmaceutical Society (RPS) and National Pharmacy Association (NPA) have both urged the new health secretary Steve Barclay to back the 'pharmacy first' approach in England as mentioned by his predecessor on numerous occasions. "Sajid Javid recognised the vital role of community pharmacy and the potential of a 'Pharmacy First' to support patient access to care. I would urge the new Health Secretary to see this through to completion," said chair of RPS in England Thorrun Govind. Thorrun hopes the new health secretary will engage with pharmacy leaders about how we can make the most of our health and care workforce to support the NHS recovery, including reducing health inequalities, managing the growing cost of long-term conditions, and utilising the enhanced skills of Pharmacist Independent Prescribers. Commenting on the new appointment, she said: "This is a crucial time for the future of health and care - with continued pressures on teams, changes to NHS structures and organisations, and the need for long-term investment in the workforce. "With a 'refresh' of the NHS Long-Term Plan and the Government's workforce plan expected later this year, these must support a more ambitious approach to advancing the clinical role of pharmacists across the NHS to better meet changing patient demand, backed by investment in pharmacy education and training.

Keith Ridge, who retired from the role of England's chief pharmaceutical officer this month, has written to the NHS regional directors regarding a package to empower community pharmacies to implement clinical services in their integrated care systems. Though details about this letter are not available, Malcolm Harrison, chief executive officer of the Company Chemists' Association, welcomed the move saying: "It is a positive step towards the greater integration of community pharmacy care into the NHS. "It is vital for the NHS that patients can benefit from the clinical care services set out in the Community Pharmacy Contractual Framework." Harrison, however, highlighted that while pharmacies are being pushed to do more, the efforts to introduce new clinical services should be supported with "sustainable funding and material actions to increase workforce numbers in the sector." "We are concerned that without the funding and people in place, the desired volume of necessary services cannot be delivered, no matter how well coordinated."

Patient safety should remain a top priority in any healthcare setting. People should always receive the right advice, and pharmacists aren't 'GPs on the cheap.' Staff should be fully trained, and medical equipment should be correctly maintained at all times. In turn, this helps create a safer environment for patients and professionals alike. In this article, we'll discuss some of the factors that can enhance patient safety in healthcare settings. AUTOMATION AND MONITORING Automating processes within a facility can help streamline operations. This has the potential to reduce or eliminate human error that could result in serious injury or death. In addition, automated systems often provide instant alerts when something goes wrong - allowing medical staff to react quickly and appropriately. Automated solutions can help facilities achieve hand hygiene monitoring standards, and it's possible to schedule a demo and see their outcomes. They can reduce staff sick time and HAIs, as well as Joint Commission citations and associated costs. Monitoring helps ensure compliance with safety protocols. It's essential for improving patient safety and gaining data on all aspects of a facility's operations. It also helps organizations track the effectiveness of their protocols and procedures over time. This helps them constantly evaluate and refine their policies, to maximize patient safety benefits. ADEQUATE STAFFING In order to provide quality care, it's essential to have enough staff on hand to meet patient needs and ensure all protocols are being followed. Without this, healthcare providers may struggle to provide prompt, efficient care - which can put patient safety at risk. Adequate staffing levels should be determined by a variety of factors. They include patient numbers, the complexity of care required, and the size and layout of the facility.

The Professional Records Standards Body (PRSB), which develops information standards for health and social care records, has appointed Professor Reecha Sofat as the new Chair. She will assume the role at the end of October 2024, succeeding Professor Maureen Baker CBE, who will step down after seven years as Chair of the PRSB. A Clinical Pharmacologist, Professor Sofat has held many leadership roles across the NHS, academia and scientific societies. Professor Sofat is Breckenridge Chair of Clinical Pharmacology at the University of Liverpool. She practices general internal medicine and is also an Associate Director at the British Heart Foundation (BHF) Data Science Centre (DSC) which is led by Health Data Research UK (HDRUK). With a passion for data science and extensive clinical and research insights, Professor Sofat is focused on embedding research into routine health and social care. She said: "I am passionate about using the rich health data that is already collected across NHS and social care to better understand the causes and consequences of disease and improve health outcomes.

The Company Chemists' Association (CCA) has published a 'pharmacy paradox paper' which outlines how community pharmacy can match the ambition amidst the workforce crisis. The sector is experiencing a workforce crisis, exacerbated by NHS recruitment of community pharmacists into primary care networks. Pharmacies are also facing a significant increase in demand on services. CCA said, "A stretched and reduced pharmacy workforce is having to deliver more and more. This is unsustainable." "Unless the tension between ambition and capacity is addressed, there is a risk that community pharmacies will not only not meet their potential, but the existing offer could be compromised." Therefore, the association has set out solutions to resolve the current paradox between ambition and reality.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

The Health and Social Care Select Committee (HSCC) on Tuesday held the first session in their pharmacy inquiry, with a panel of experts discussing the key issues facing community pharmacies in the country. Representatives from community pharmacy associations highlighted some of their biggest challenges and their vision for the future, as well as actions that government and NHS England can take to address those challenges for a better future for the sector. Opening the session, the Committee's vice-chair, Rachel Maskell MP, asked the representatives if they felt the government was ambitious enough in what it believes community pharmacy can do to address NHS pressures, or are pharmacists being held back by issues around workforce funding, contracting, and technological changes. Malcolm Harrison, Chief Executive, Company Chemists' Association (CCA), expressed that the government is not ambitious enough, saying "there's always opportunity to be more ambitious".

The Professional Pharmacists Association (PDA) has demanded efforts to secure greater support and recognition for community pharmacists from governmental bodies. In its written evidence provided to the Health and Social Care select committee's pharmacy inquiry, the PDA raised concerns about the well-being of pharmacists, specifically for those who belong to minority ethnic groups and race and are subjected to bullying, harassment, and ill-treatment. The association highlighted issues in the workplace that impact pharmacists' health and well-being, including chronic understaffing, sub-standard working environments, an absence of protected training time, and experiences of racism, violence, and abuse. Parallel to the PDA's advocacy, the Royal Pharmaceutical Society (RPS) is intensifying calls for prioritising workforce wellbeing within the pharmacy domain. Stressing the pivotal role of workforce retention in addressing current challenges, RPS emphasises the need for robust support mechanisms and equitable access to mental health services.

The Company Chemist Association (CCA) highlighted its concerns around the recruitment of pharmacists into Primary Care Networks as well as the need for additional investment. Commenting on the Ipsos survey findings, the Malcolm Harrison, the Chief executive of the CCA said: "We welcome the findings of the Ipsos survey, confirming that patients value the quality of service and advice community pharmacies routinely provide. "We are very concerned however that this cancer detection pilot, and all other pharmacy services, are at risk if the NHS is not prepared to inject urgently needed funding into the sector." He stated that without substantial investment, "we will see the continued erosion of the service pharmacies can provide." In addition to the need for critical additional funding the association is also calling on the NHS to pause the recruitment of pharmacists into GP surgeries. He said: "Patients are suffering because the demand for pharmacists in England is now significantly greater than that which the existing workforce can deliver."

Preet Kaur Gill, Shadow Minister for Primary Care and Public Health, has paid a recent visit to a community pharmacy in Staffordshire to personally experience the services it provides to patients, while staying updated on the latest sector developments. Her visit to Eason's Pharmacy in Tamworth on September 22nd marked her first since assuming new responsibilities for pharmacy policy matters within Labour's health team. Gill was also joined by a member of the National Pharmacy Association staff. The Minister received a comprehensive briefing on Eason's Pharmacy from its third-generation owner, Kieran Eason (R). He outlined the NHS services, which include the New Medicines Service and blood pressure monitoring, and showcased two consultation rooms and an operational dispensary. "It's great that Preet came to learn firsthand about the challenges we face and the substantial potential of community pharmacies nationwide," Eason said. "As an independent prescriber, I have the expertise to provide even more convenient care, but the current funding levels severely limit our contribution."

A recent report by the British Generic Manufacturers Association (BGMA) has shed light on ongoing supply challenges in England's generic medicines market, revealing significant issues impacting patient care. The report highlights significant challenges faced in supply of medicines as currently, 51.72 per cent of generics in short supply lack licensed alternatives, posing substantial hurdles to ensuring continuous patient care. Additionally, 39.08 per cent of affected generics are branded, indicating widespread disruptions across the market. A notable 26.44 per cent of generics experiencing shortages have been affected for over six months, highlighting persistent difficulties in supply chain management. The report indicates that 0.15 per cent of generic medicine presentations listed in the Drug Tariff are currently facing supply issues, impacting accessibility nationwide.

PAGB, the prominent consumer healthcare association, has appointed a new Vice-President following the departure of Richard Holme from PAGB's Board earlier this year. Brian R. Fischel, who currently serves as Regional Director & General Manager for UK and Ireland at Reckitt, is set to take on the new Vice-President role at PAGB. Bringing extensive international experience as Vice-President at UK trade association representing manufacturers of branded over-the-counter medicines, medical devices and food supplements, Fischel has over eight years at Reckitt managing various global health territories. His election in the leadership role in June positions him alongside Bas Vorsteveld, President, and Mike Knowland, Vice President, completing PAGB's executive team. Michelle Riddalls, CEO of PAGB, expressed optimism about Brian's appointment, emphasising his alignment with PAGB's strategic objectives.

The National Pharmacy Association has published a medium-term prospectus for the development of pharmacy services, calling it a challenge to old ways of thinking and an opportunity to redefine the sector's role in the NHS. It follows months of dialogue with NPA members about what a clinical future could look like for the sector. The document - Making Changes Meeting Needs - will be shared with the King's Fund and Nuffield Trust who are currently working on a new vision for the future on behalf of Community Pharmacy England. NPA chair, Nick Kaye, said: "Building out from the existing portfolio of services, there are some major opportunities within this decade, encompassing prevention, medicines optimisation, long term medical conditions and urgent care.